Resource Summary Report

Generated by NIF on Sep 22, 2026

LS411N

RRID:CVCL_1385
Type: Cell Line

Proper Citation

RRID:CVCL_1385

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1385

Proper Citation: RRID:CVCL_1385

Description: Cell line LS411N is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cecum adenocarcinoma

Defining Citation: PMID:1389533, PMID:1617643, PMID:8464898, PMID:8895552, PMID:10737795, PMID:11226274, PMID:11414198, PMID:12068308, PMID:16418264, PMID:16854228, PMID:18258742, PMID:19927377, PMID:20164919, PMID:20570890, PMID:20606684, PMID:22460905, PMID:23272949, PMID:23932154, PMID:24755471, PMID:25926053, PMID:25984343, PMID:26537799, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28854368, PMID:29101300, PMID:29444439, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31395879, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LS411N

Synonyms: LS-411N, LS-411, LS 411, LS411

Cross References: CLO:CLO_0007406, CLO:CLO_0009968, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2159,

BioGRID_ORCS_Cell_line:935, BioSample:SAMN03472557, BioSample:SAMN10988286, cancercelllines:CVCL_1385, Cell_Model_Passport:SIDM00660, ChEMBL-Cells:CHEMBL3308268, ChEMBL-Targets:CHEMBL2366189, ColonAtlas:LS411, Cosmic:685868, Cosmic:887215, Cosmic:907794, Cosmic:948862, Cosmic:985999, Cosmic:995401, Cosmic:1043821, Cosmic:1310951, Cosmic:1312306, Cosmic:1479613, Cosmic:1995491, Cosmic:2301999, Cosmic:2760088, Cosmic:2800575, Cosmic-CLP:907794, DepMap:ACH-000985, EGA:EGAS00001000978, GDSC:907794, GEO:GSM513913, GEO:GSM514300, GEO:GSM741269, GEO:GSM887280, GEO:GSM888355, GEO:GSM1006219, GEO:GSM1006220, GEO:GSM1006221, GEO:GSM1346848, GEO:GSM1374637, GEO:GSM1448140, GEO:GSM1670061, IARC_TP53:21479, IARC_TP53:21751, LiGeA:CCLE_191, LINCS_LDP:LCL-1337, MetaboLights:MTBLS227, PharmacoDB:LS411N_863_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_1385, PubChem_Cell_line:CVCL_1385, SKY/M-FISH/CGH:5011, Wikidata:Q54903069

ID: CVCL_1385

Record Creation Time: 20220427T220735+0000

Record Last Update: 20260920T004406+0000

Ratings and Alerts

No rating or validation information has been found for LS411N.

No alerts have been found for LS411N.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Renner F, et al. (2026) Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer. Molecular cancer therapeutics, 25(4), 599.

Martinez-Martinez D, et al. (2025) Chemotherapy modulation by a cancer-associated microbiota metabolite. Cell systems, 16(9), 101397.

Castro J, et al. (2025) A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. Cancer research, 85(4), 758.

Sogari A, et al. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. Cell reports. Medicine,

5(2), 101376.

Thomas JD, et al. (2024) Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates. Molecular cancer therapeutics, 23(4), 541.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. Cell reports. Medicine, 5(5), 101523.

Coelho MA, et al. (2023) Base editing screens map mutations affecting interferon-?? signaling in cancer. Cancer cell, 41(2), 288.

Miller AL, et al. (2023) DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer. Cancer research, 83(11), 1800.

Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(23), 5190.

Ferrandon S, et al. (2020) CoA Synthase (COASY) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer. Cancer research, 80(2), 334.